6-O-benzylguanine

Generic Name: 6-O-benzylguanine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₁N_₅O

CAS Number: 19916-73-5

Unique Ingredient Identifier: 01KC87F8FE

Background: 6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Phase 2

Recruiting

Conditions: Glioblastoma Multiforme
Glioblastoma Multiforme, Adult
Supratentorial Gliosarcoma
Supratentorial Glioblastoma

Interventions: Biological: P140K-MGMT
Drug: O6-benzylguanine
Radiation: Photon Based Radiotherapy
Drug: temozolomide
Drug: Filgrastim
Drug: carmustine

First Posted Date: 2021-09-22

Last Posted Date: 2024-07-23

Lead Sponsor: Leland Metheny

Target Recruit Count: 16

Registration Number: NCT05052957

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Phase 1

Withdrawn

Conditions: Human Immunodeficiency Virus 1 Positive
Stage I Adult Hodgkin Lymphoma
Stage I Adult Non-Hodgkin Lymphoma
Stage II Adult Hodgkin Lymphoma
Stage II Adult Non-Hodgkin Lymphoma
Stage III Adult Hodgkin Lymphoma
Stage III Adult Non-Hodgkin Lymphoma
Stage IV Adult Hodgkin Lymphoma
Stage IV Adult Non-Hodgkin Lymphoma

Interventions: Biological: C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs
Drug: Carmustine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: O6-Benzylguanine
Drug: Plerixafor

First Posted Date: 2015-01-22

Last Posted Date: 2018-11-20

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT02343666

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Not Applicable

Withdrawn

Conditions: HIV-associated Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides/Sezary Syndrome
Splenic Marginal Zone Lymphoma
Stage IV AIDS-related Lymphoma
AIDS-related Diffuse Small Cleaved Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
Hepatosplenic T-cell Lymphoma
Peripheral T-cell Lymphoma

Interventions: Drug: carmustine
Drug: cytarabine
Drug: melphalan
Drug: etoposide
Drug: O6-benzylguanine
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2013-01-17

Last Posted Date: 2015-05-07

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT01769911

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

BG & TMZ Therapy of Glioblastoma Multiforme

Phase 1

Completed

Conditions: Glioblastoma Multiforme

Interventions: Biological: MGMTP140K-encoding retroviral vector
Drug: O6-benzylguanine
Drug: temozolomide
Other: laboratory biomarker analysis
Procedure: autologous hematopoietic stem cell transplantation
Procedure: in vitro-treated peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2011-01-04

Last Posted Date: 2023-03-02

Lead Sponsor: Stanton Gerson MD

Target Recruit Count: 10

Registration Number: NCT01269424

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Phase 1

Completed

Conditions: Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Carmustine
Other: Laboratory Biomarker Analysis
Drug: O6-Benzylguanine

First Posted Date: 2009-08-18

Last Posted Date: 2018-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00961220

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 1 locations

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Phase 1

Terminated

Conditions: Gliosarcoma
Glioblastoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Biological: Filgrastim
Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Drug: O6-Benzylguanine
Drug: Plerixafor
Radiation: Proton Beam Radiation Therapy
Drug: Temozolomide

First Posted Date: 2008-04-30

Last Posted Date: 2022-05-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00669669

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

Phase 2

Terminated

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: O6-benzylguanine
Drug: temozolomide

First Posted Date: 2007-02-19

Last Posted Date: 2017-03-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00436436

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
NCI - Neuro-Oncology Branch, Bethesda, Maryland, United States

O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: O6-benzylguanine
Drug: temozolomide

First Posted Date: 2006-01-11

Last Posted Date: 2022-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00275002

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 8 locations

Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas

Not Applicable

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2005-11-15

Last Posted Date: 2014-01-06

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Registration Number: NCT00253487

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-08-16

Last Posted Date: 2013-02-20

Lead Sponsor: Duke University

Target Recruit Count: 56

Registration Number: NCT00003348

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy